The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.
Hair cloning for hair loss is unlikely to be available or affordable in the next 10 years. Current treatments like Minoxidil, finasteride, and RU58841 are still the main options, with skepticism about new advancements.
PP405 shows promise for hair growth but may need continuous use like Minoxidil. Current treatments include Minoxidil, finasteride, and dutasteride, with skepticism about a true cure due to financial interests.
The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
A user shared their positive experience with a hair transplant at Eugenix in India, noting the professionalism and natural results. They mentioned using 2815 grafts and discussed the clinic's controversial name, but did not mention using specific treatments like Minoxidil or finasteride.
Using finasteride before a hair transplant can prevent further hair loss and make the transplant look more natural. Patients should continue using finasteride until hair cloning becomes available.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.
A user started working with a leading hair cloning lab to address their hair loss. They have a computer science background and will assist with data science.
A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.
The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.
HairClone plans to start hair multiplication services in 2022. Users discuss various treatments like Minoxidil, finasteride, PRP, and hair cloning, expressing both hope and skepticism about the technology and its costs.
Stem cell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Using lice as an alternative to microneedling for hair loss treatment, with concerns about effectiveness and practicality. Some users humorously suggest genetically altering lice to produce beneficial compounds.